Published 2 years ago • loading... • Updated 2 years ago

Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today's Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc. - Sorrento Therapeutics (NASDAQ:SRNE), Scilex Holding (NASDAQ:SCLX)

Summary by Ground News

Scilex Holding Company, majority-owned by Sorrento Therapeutics, Inc., is an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products. Scilex launched its first commercial product in October 2018, in-licensed a commercial Product in June 2022, and is developing its late-stage pipeline, which includes a pivotal Phase 3 candidate.

3 Articles

All

Left

Center

Right

Benzinga

Center

Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today's Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc. - Sorrento Therapeutics (NASDAQ:SRNE), Scilex Holding (NASDAQ:SCLX)

SAN DIEGO and PALO ALTO, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex")), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento")) and an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, together with Sorrento, issued the following statements: Henry Ji,…

2 years ago·New York, United States

Read Full Article